We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
Cap. Flow
-$99.6M
Cap. Flow %
-3.9%
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$20M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.2M
3
AMGN icon
Amgen
AMGN
+$14.1M
4
PODD icon
Insulet
PODD
+$13.3M
5
BAX icon
Baxter International
BAX
+$11.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$31.7M
2
CI icon
Cigna
CI
+$22.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$22.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.28%
2 Real Estate 2.09%
3 Miscellaneous 1.37%
4 Industrials 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
76
Intellia Therapeutics
NTLA
$1.8B
$6.29M 0.25%
154,269
– –
LTC
77
LTC Properties
LTC
$2.19B
$6.02M 0.24%
182,293
– –
SBRA icon
78
Sabra Healthcare REIT
SBRA
$5.27B
$6.01M 0.24%
510,660
– –
SNN icon
79
Smith & Nephew
SNN
$12.1B
$5.86M 0.23%
181,710
– –
KDNY
80
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$5.8M 0.23%
150,863
+67,363
+81% +$1.73M
WST icon
81
West Pharmaceutical
WST
$23.7B
$5.75M 0.23%
15,036
– –
CERE
82
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$5.61M 0.22%
176,483
– –
LIVN icon
83
LivaNova
LIVN
$4.43B
$5.58M 0.22%
108,480
+44,600
+70% +$2.09M
MDRX
84
DELISTED
Veradigm Inc. Common Stock
MDRX
$5.4M 0.21%
428,580
– –
A icon
85
Agilent Technologies
A
$43.4B
$5.19M 0.2%
43,191
– –
MRNS
86
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.46M 0.17%
411,101
-45,679
-10% -$391K
QURE icon
87
uniQure
QURE
$3.38B
$4.08M 0.16%
356,280
-296,166
-45% -$5.61M
COR icon
88
Cencora
COR
$61.5B
$3.93M 0.15%
20,417
– –
MPT
89
Medical Properties Trust
MPT
$2.44B
$3.81M 0.15%
411,743
– –
ONC
90
BeOne Medicines Ltd
ONC
$41.5B
$3.74M 0.15%
20,952
– –
IONS icon
91
Ionis Pharmaceuticals
IONS
$10.1B
$3.6M 0.14%
87,840
– –
BCRX icon
92
BioCryst Pharmaceuticals
BCRX
$2.51B
$3.55M 0.14%
504,528
– –
RETA
93
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3.49M 0.14%
34,250
+16,400
+92% +$1.55M
TEVA icon
94
Teva Pharmaceuticals
TEVA
$42.5B
$3.46M 0.14%
459,651
– –
WELL icon
95
Welltower
WELL
$172B
$3.36M 0.13%
41,484
– –
HR icon
96
Healthcare Realty
HR
$6.51B
$3.29M 0.13%
174,686
– –
VTR icon
97
Ventas
VTR
$47.1B
$3.15M 0.12%
66,681
– –
IBB icon
98
iShares Biotechnology ETF
IBB
$10.5B
$3.12M 0.12%
24,569
– –
DOC icon
99
Healthpeak Properties
DOC
$14.5B
$3.02M 0.12%
150,392
– –
AKRO
100
DELISTED
Akero Therapeutics
AKRO
$2.87M 0.11%
+61,497
New +$2.82M
2 3
4
5 6

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Tekla Capital Management held 186 positions worth $2.56B, down 2.7% from $2.63B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $99.6M in Q2 2023, closing 20 positions and reducing 32 holdings. Its most notable exit was Travere Therapeutics, an estimated $9.41M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.

Against the trend, Tekla Capital Management opened a new position in Insulet worth $12.6M.

  • Tekla Capital Management's largest Q2 2023 buy was Insulet: 43,847 shares worth $12.6M.
  • Tekla Capital Management added most to Merck in Q2 2023, an estimated $20M increase.
  • Tekla Capital Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $31.7M.
  • Tekla Capital Management fully exited Travere Therapeutics in Q2 2023, selling an estimated $9.41M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.56B portfolio in Q2 2023.
  • Tekla Capital Management opened 9 new positions and closed 20 in Q2 2023.
  • Tekla Capital Management's portfolio value fell 2.7% quarter-over-quarter to $2.56B.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.